Found Health Reviewed (2026) → Dr. Rekha Kumar's Science-First GLP-1 Platform vs the Celebrity Tier

Found Health's structural position in the 2026 U.S. telehealth GLP-1 category is editorially unique — and the reason this review settles at the highest editor's rating we've awarded in our 14-platform set (4.7/5, edging JRNYS at 4.6 and HealthRX.com at 4.6). The differentiator isn't a single feature; it's the combination of five rare-in-our-set institutional signals, all surfaced publicly. First, the explicit science-first editorial positioning: Found's about-page meta-description literally reads "Discover weight care backed by science, not just celebrities. Focus on long-term wellness with evidence-based solutions." That's a deliberate competitive jab at founder-celebrity-led brands in the category — and it's substantively backed by named medical leadership credentials. Second, the named medical leadership: Senior Medical Advisor Dr. Rekha Kumar MD, with a verifiable LinkedIn profile documenting her tenure as Medical Director of the American Board of Obesity Medicine (ABOM) — the U.S. specialty-board credentialing organization for obesity medicine physicians. That's external-credential medical leadership at a level we haven't seen elsewhere in our 14-platform 2026 review set. Third, the broadest medication menu: 15 distinct treatments including the proprietary Foundayo™ daily pill, compounded GLP-1, eight FDA-approved branded GLP-1s, and four non-GLP-1 FDA-approved anti-obesity options. Fourth, the published outcome aggregate: 12% average body weight loss at 1 year based on n=1,773 users self-reporting weekly — explicit sample size, measurement frequency, and follow-up duration. Fifth, the B2B and health-plan partnership infrastructure: Found for Business, Found for Health Plans, and a GLP-1 Coverage Checker tool — institutional infrastructure rare in the consumer-direct telehealth GLP-1 category.

Dr. Rekha Kumar — the former ABOM Medical Director

Found Health's Senior Medical Advisor is Dr. Rekha Kumar MD. Her verifiable LinkedIn profile documents her credentials as a board-certified physician with extensive expertise in obesity medicine and endocrinology, including her tenure as Medical Director of the American Board of Obesity Medicine (ABOM). The ABOM is the U.S. specialty-board credentialing organization for obesity medicine physicians — meaning Dr. Kumar previously held the senior clinical-credentialing role for the U.S. obesity medicine physician community. This is editorially distinctive medical leadership.

By comparison with other named-medical-leadership platforms in our 14-platform 2026 review set:

• Found Health: Dr. Rekha Kumar — former ABOM Medical Director (specialty-board level)
• JRNYS: Dr. Henry Legere — Columbia-trained, Harvard immunologist (institutional pedigree)
• MyStart Health: Dr. Ritu Chopra — Beverly Hills MD (named CMO)
• Tuyo Health: Dr. German Echeverry — named Co-Founder & CEO
• BreezeMeds: Dr. Ana Lisa Carr (NPI 1689841744) + Dr. Kelly Tenbrink (NPI 1346482684) — verifiable NPIs
• Fella Health: 3-advisor panel
• FuturHealth: 3 named medical advisors
• GoodGirlRx: Savannah Chrisley (named celebrity founder, not medical leader)

The ABOM Medical Director credential is structurally different from named-but-individual-physician credentials. It represents prior senior leadership at the specialty board level — the equivalent of having been Medical Director of the American Board of Cardiology or Endocrinology before founding/joining a telehealth platform. This kind of external specialty-board credentialing background is rare in U.S. telehealth GLP-1.

The 15-medication menu — broadest in our entire 2026 review set

Found Health's medication menu is the broadest we've documented in our 14-platform 2026 review set. Fifteen distinct treatments spanning compounded GLP-1, FDA-approved branded GLP-1, FDA-approved non-GLP-1 anti-obesity, and adjunct metabolic therapies:

Compounded GLP-1 options:

• Compounded Semaglutide — once-weekly injection, same active ingredient as Wegovy/Ozempic
• Compounded Tirzepatide — once-weekly dual-incretin injection, same active ingredient as Zepbound/Mounjaro

Proprietary platform medication:

• Foundayo™ — Found's proprietary daily pill formulation. One of only two platform-developed daily pill products we've documented (FuturHealth's Foundayo daily pill is the other). For buyers who prefer daily oral dosing over weekly injection, this is structurally distinctive.

FDA-approved branded GLP-1 medications:

• Ozempic® — semaglutide for type 2 diabetes (off-label for weight loss)
• Mounjaro® — tirzepatide for type 2 diabetes (off-label for weight loss)
• Zepbound® — tirzepatide for chronic weight management
• Wegovy® — semaglutide for chronic weight management
• Saxenda® — liraglutide for chronic weight management
• Rybelsus® — FDA-approved oral semaglutide (needle-free FDA-approved)
• Trulicity® — dulaglutide for type 2 diabetes
• Victoza® — liraglutide for type 2 diabetes

Non-GLP-1 FDA-approved anti-obesity (rare):

• Contrave® — FDA-approved bupropion/naltrexone combination for chronic weight management. Rare in our review set.
• Topiramate — non-GLP-1 anti-obesity adjunct
• Zonisamide — non-GLP-1 anti-obesity adjunct
• Metformin — anti-obesity / metabolic adjunct

The non-GLP-1 options (Contrave, Topiramate, Zonisamide, Metformin) are editorially distinctive. Most platforms in our 2026 review set focus exclusively on GLP-1 and GIP/GLP-1 medications. Found's inclusion of FDA-approved non-GLP-1 anti-obesity medications reflects the clinical reality that some patients have GLP-1 contraindications, intolerable GLP-1 side effects, or specific clinical situations where non-GLP-1 anti-obesity therapy is more appropriate. Having those options on the same platform — under the supervision of the same providers — is editorially valuable for clinical flexibility.

The published 1,773-user outcome study — explicit methodology

Found Health publishes an outcome aggregate footnote that's editorially distinctive for its explicit methodology disclosure:

"Real users, paid for appearance. Individual results may vary. In 1 year, Found users lost an average of 12% body weight. Results based on data from 1,773 users who reported their weight at least 1 time/week on avg. for 1 year."

What makes this editorially distinctive: explicit sample size (n=1,773), explicit measurement frequency (weekly), explicit follow-up duration (1 year), explicit "real users, paid for appearance" disclosure for the testimonial videos shown alongside. Most platforms in our review set publish either shorter-horizon outcome data (Tuyo Health's 7-lbs-in-first-month aggregate) or generic claims without methodology (most platforms display "average loss of X lbs" without sample size or measurement methodology).

The 12% body weight loss figure is conservatively lower than the published clinical trial benchmarks:

• STEP-1 trial (semaglutide, FDA-approved): 14.9% body weight loss at 68 weeks
• SURMOUNT-1 trial (tirzepatide, FDA-approved): 22.5% body weight loss at 72 weeks (15 mg dose)
• Found real-world n=1,773: 12% body weight loss at 1 year

The fact that Found's real-world aggregate (12%) is lower than the published trial benchmarks (14.9% STEP-1 / 22.5% SURMOUNT-1) is editorially honest — it reflects real-world dose-titration variation, adherence variation, and the heterogeneous medication mix across Found's 15-medication menu. Aggregate outcomes that match or exceed trial benchmarks would be editorially suspicious; Found's aggregate is conservatively framed and methodologically transparent.

B2B and health-plan partnership infrastructure — rare in our review set

Found Health operates two B2B-and-institutional channels alongside its consumer-direct path:

• Found for Business at joinfound.com/business — employer benefit programs allowing companies to offer Found's weight care as a benefit to employees.
• Found for Health Plans at joinfound.com/health-plans — insurance partnership programs.
• GLP-1 Coverage Checker tool at joinfound.com/glp1-checker — surfaces insurance coverage for branded medications.

This institutional infrastructure is editorially rare in our 14-platform 2026 review set. Most consumer-direct telehealth GLP-1 platforms don't operate dedicated employer benefit or health plan partnership channels. For buyers whose employers offer Found as a benefit — or who have insurance that covers weight care under a health-plan partnership — the cost economics may be dramatically more favorable than cash-pay consumer-direct pricing. The Measured platform offers active insurance prior-authorization handling for individual consumers; Found's B2B/health-plan infrastructure goes one level higher — partnering at the employer and insurance-plan level rather than per-patient.

Are Found Health medications compounded or FDA-approved?

Found Health offers both — and the 15-medication menu is heavily weighted toward FDA-approved branded options. Eight FDA-approved branded GLP-1 medications (Ozempic, Mounjaro, Zepbound, Wegovy, Saxenda, Rybelsus, Trulicity, Victoza) plus four FDA-approved non-GLP-1 anti-obesity options (Contrave, Topiramate, Zonisamide, Metformin) means twelve of the fifteen options are FDA-reviewed finished drug products. The compounded options (Compounded Semaglutide, Compounded Tirzepatide) and the proprietary Foundayo daily pill are the three non-FDA-approved options.

Found Health GLP-1 side effects

Side effects are the same as any GLP-1 medication. Found's published Refund Policy, Telehealth Consent, and Resource Center surface standard FDA-mandated safety information:

• Boxed warning: Thyroid C-cell tumor risk; do not use if you or family member has history of MTC or MEN 2 syndrome.
• Serious side effects requiring monitoring: Acute pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury, serious allergic reactions, acute gallbladder disease, increase in heart rate, suicidal behavior and ideation monitoring.
• Common side effects: Nausea, vomiting, diarrhea, stomach pain, constipation — particularly during titration weeks 1-4.

The breadth of Found's medication menu — including non-GLP-1 alternatives like Contrave, Topiramate, Zonisamide, and Metformin — provides clinical flexibility for patients who experience intolerable GLP-1 side effects. Dr. Kumar's ABOM-level obesity medicine background is editorially aligned with this multi-medication approach.

Who Found Health is best for

Found Health is a strong fit if you:

• Value science-first editorial positioning — Found explicitly publishes "backed by science, not just celebrities"
• Want named, externally-credentialed medical leadership — Dr. Rekha Kumar (former ABOM Medical Director, verifiable LinkedIn)
• Want the broadest medication menu in our 14-platform 2026 review set — 15 options
• Specifically want FDA-approved non-GLP-1 anti-obesity options (Contrave, Topiramate, Zonisamide, Metformin) rare elsewhere
• Want the proprietary Foundayo™ daily pill
• Appreciate published outcome data with explicit methodology (n=1,773, weekly reporting, 12% at 1 year)
• Have an employer or insurance offering Found as a benefit — through For Business or For Health Plans
• Want a microdosing program
• Appreciate a full clinical tool suite (BMI, BMR, calorie, protein, waist-to-hip calculators)
• Value full LegitScript certification (seal 7792020)

Found Health is not the best fit if you:

• Specifically want the absolute lowest published starting price in upfront format (see JRNYS $89/mo, HealthRX.com $99/mo, bmiMD $99/mo)
• Specifically want a celebrity-founder brand-personality fit (see GoodGirlRx with Savannah Chrisley, G-Plans with Philip Goglia)
• Want a concrete money-back weight-loss outcome guarantee with specific time threshold (see Clinic Secret's 6/12-month tiered)
• Want a named individual compounding pharmacy partner publicly disclosed (see HealthRX.com's Manifest Pharmacy)
• Are pregnant, nursing, under 18, or have GLP-1 contraindications

Found Health vs alternatives

Found Health is the only platform in our 14-platform 2026 review set that simultaneously offers: (a) externally-credentialed named medical leadership at the specialty-board level (Dr. Kumar's former ABOM Medical Director role), (b) the broadest medication menu (15 treatments), (c) the most methodologically transparent outcome aggregate (n=1,773, weekly, 1 year, 12%), and (d) B2B + health-plan partnership institutional infrastructure. That four-way combination is structurally unique — and the editorial reason this review settles at 4.7/5, the highest rating in the entire set.

Found Health pros and cons

Found Health sign-up & ongoing-care checklists

Found Health frequently asked questions

Honest verdict — should you choose Found Health?

Found Health earns the highest editor's rating in our entire 14-platform 2026 review set at 4.7/5 — edging JRNYS (4.6/5) and HealthRX.com (4.6/5) on the strength of four structurally distinctive features. First, externally-credentialed named medical leadership: Dr. Rekha Kumar's prior role as Medical Director of the American Board of Obesity Medicine is editorial credibility at a level we haven't documented elsewhere. Second, the broadest medication menu in our review set: 15 treatments including the rare non-GLP-1 anti-obesity options (Contrave, Topiramate, Zonisamide, Metformin) and the proprietary Foundayo daily pill. Third, the published outcome aggregate with explicit methodology: n=1,773 users, weekly self-reporting, 1-year follow-up, 12% body weight loss — conservatively lower than published trial benchmarks, which is editorially honest. Fourth, the B2B + health-plan partnership infrastructure: Found for Business, Found for Health Plans, and the GLP-1 Coverage Checker tool represent institutional capabilities rare in the consumer-direct telehealth GLP-1 category.

What pulls the rating from a perfect 5/5 is straightforward: pricing isn't granularly published on the about page — surfaced via the plans-and-pricing intake. The breadth of the 15-medication menu requires provider matching. The named individual compounding pharmacy partner isn't publicly disclosed (HealthRX.com names Manifest Pharmacy; BreezeMeds names 4 partners with phone numbers). None of these are fatal — they're the practical trade-offs of a platform optimized for clinical breadth and institutional partnership rather than absolute price transparency.

The bottom line

If you value science-first editorial positioning with externally-credentialed named medical leadership (Dr. Kumar's former ABOM Medical Director credential is unique in our review set), want the broadest medication menu in the category (15 treatments, including rare non-GLP-1 anti-obesity options), appreciate published outcome data with explicit methodology, and value institutional partnership infrastructure (employer + insurance plan partnerships), Found Health is editorially the strongest platform we've documented. If you specifically want the absolute lowest published starting price in upfront format, JRNYS at $89/mo or HealthRX.com at $99/mo are explicitly priced. If you want celebrity-founder brand-personality alignment, GoodGirlRx with Savannah Chrisley is the editorially appropriate alternative.

Published: June 3, 2026 · Last updated: June 3, 2026 · Verified: June 2026 · Spot a factual issue? Tell our editors.